bomedemstat
imago biosciences
[]
imago biosciences presents positive data from ongoing phase 2 study of bomedemstat in advanced myelofibrosis at eha 2022 - as of the data cutoff date of 29 april 2022, in addition to improvements in the standard metrics of spleen volume reduction and sy... 
CEO Of Digital Media Online